APA (7th ed.) Citation

Cestari, T. F., Souza, C. d. S., Azulay-Abulafia, L., Romiti, R., Carvalho, A. V., Castro, C. C. S. d., . . . Oyafuso, L. K. M. Efficacy and safety of risankizumab versus methotrexate in patients with moderate-to-severe plaque psoriasis: Results from IMMbrace, a randomized, double-blind, phase 3 study with an open-label extension period in Brazil. Sociedade Brasileira de Dermatologia.

Chicago Style (17th ed.) Citation

Cestari, Tania F., et al. Efficacy and Safety of Risankizumab Versus Methotrexate in Patients with Moderate-to-severe Plaque Psoriasis: Results from IMMbrace, a Randomized, Double-blind, Phase 3 Study with an Open-label Extension Period in Brazil. Sociedade Brasileira de Dermatologia.

MLA (9th ed.) Citation

Cestari, Tania F., et al. Efficacy and Safety of Risankizumab Versus Methotrexate in Patients with Moderate-to-severe Plaque Psoriasis: Results from IMMbrace, a Randomized, Double-blind, Phase 3 Study with an Open-label Extension Period in Brazil. Sociedade Brasileira de Dermatologia.